FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022036412> ?p ?o ?g. }

• W2022036412 endingPage "40191" @default.
• W2022036412 startingPage "40180" @default.
• W2022036412 abstract "Reduction of brain amyloid-β (Aβ) has been proposed as a therapeutic target for Alzheimer disease (AD), and microglial Aβ phagocytosis is noted as an Aβ clearance system in brains. Galantamine is an acetylcholinesterase inhibitor approved for symptomatic treatment of AD. Galantamine also acts as an allosterically potentiating ligand (APL) for nicotinic acetylcholine receptors (nAChRs). APL-binding site is located close to but distinct from that for acetylcholine on nAChRs, and FK1 antibody specifically binds to the APL-binding site without interfering with the acetylcholine-binding site. We found that in human AD brain, microglia accumulated on Aβ deposits and expressed α7 nAChRs including the APL-binding site recognized with FK1 antibody. Treatment of rat microglia with galantamine significantly enhanced microglial Aβ phagocytosis, and acetylcholine competitive antagonists as well as FK1 antibody inhibited the enhancement. Thus, the galantamine-enhanced microglial Aβ phagocytosis required the combined actions of an acetylcholine competitive agonist and the APL for nAChRs. Indeed, depletion of choline, an acetylcholine-competitive α7 nAChR agonist, from the culture medium impeded the enhancement. Similarly, Ca(2+) depletion or inhibition of the calmodulin-dependent pathways for the actin reorganization abolished the enhancement. These results suggest that galantamine sensitizes microglial α7 nAChRs to choline and induces Ca(2+) influx into microglia. The Ca(2+)-induced intracellular signaling cascades may then stimulate Aβ phagocytosis through the actin reorganization. We further demonstrated that galantamine treatment facilitated Aβ clearance in brains of rodent AD models. In conclusion, we propose a further advantage of galantamine in clinical AD treatment and microglial nAChRs as a new therapeutic target." @default.
• W2022036412 created "2016-06-24" @default.
• W2022036412 creator A5017020283 @default.
• W2022036412 creator A5024903237 @default.
• W2022036412 creator A5026275950 @default.
• W2022036412 creator A5032064265 @default.
• W2022036412 creator A5040852969 @default.
• W2022036412 creator A5046648650 @default.
• W2022036412 creator A5056687099 @default.
• W2022036412 creator A5059350139 @default.
• W2022036412 creator A5074867425 @default.
• W2022036412 creator A5084058597 @default.
• W2022036412 creator A5088123955 @default.
• W2022036412 date "2010-12-01" @default.
• W2022036412 modified "2023-10-11" @default.
• W2022036412 title "Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors" @default.
• W2022036412 cites W1495448998 @default.
• W2022036412 cites W1511127813 @default.
• W2022036412 cites W1528383660 @default.
• W2022036412 cites W1537745645 @default.
• W2022036412 cites W1546526125 @default.
• W2022036412 cites W1567490604 @default.
• W2022036412 cites W1584669232 @default.
• W2022036412 cites W1621971853 @default.
• W2022036412 cites W1693283493 @default.
• W2022036412 cites W1965275873 @default.
• W2022036412 cites W1974884309 @default.
• W2022036412 cites W1982064952 @default.
• W2022036412 cites W2000917982 @default.
• W2022036412 cites W2007651998 @default.
• W2022036412 cites W2011198398 @default.
• W2022036412 cites W2017570770 @default.
• W2022036412 cites W2021280501 @default.
• W2022036412 cites W2022986204 @default.
• W2022036412 cites W2023531011 @default.
• W2022036412 cites W2034963833 @default.
• W2022036412 cites W2036957884 @default.
• W2022036412 cites W2043467860 @default.
• W2022036412 cites W2050106520 @default.
• W2022036412 cites W2050556307 @default.
• W2022036412 cites W2054179633 @default.
• W2022036412 cites W2059214757 @default.
• W2022036412 cites W2072837740 @default.
• W2022036412 cites W2077887990 @default.
• W2022036412 cites W2080488285 @default.
• W2022036412 cites W2088326403 @default.
• W2022036412 cites W2090236009 @default.
• W2022036412 cites W2091608383 @default.
• W2022036412 cites W2092403972 @default.
• W2022036412 cites W2092727345 @default.
• W2022036412 cites W2093374391 @default.
• W2022036412 cites W2095948686 @default.
• W2022036412 cites W2096410114 @default.
• W2022036412 cites W2096791952 @default.
• W2022036412 cites W2097485803 @default.
• W2022036412 cites W2103645895 @default.
• W2022036412 cites W2104227586 @default.
• W2022036412 cites W2105704879 @default.
• W2022036412 cites W2110888808 @default.
• W2022036412 cites W2115574704 @default.
• W2022036412 cites W2122692162 @default.
• W2022036412 cites W2135955724 @default.
• W2022036412 cites W2142943752 @default.
• W2022036412 cites W2148568069 @default.
• W2022036412 cites W2150999725 @default.
• W2022036412 cites W2152446053 @default.
• W2022036412 cites W2155997108 @default.
• W2022036412 cites W2160559062 @default.
• W2022036412 cites W2170201765 @default.
• W2022036412 cites W2195873976 @default.
• W2022036412 cites W4238596965 @default.
• W2022036412 doi "https://doi.org/10.1074/jbc.m110.142356" @default.
• W2022036412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3001000" @default.
• W2022036412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20947502" @default.
• W2022036412 hasPublicationYear "2010" @default.
• W2022036412 type Work @default.
• W2022036412 sameAs 2022036412 @default.
• W2022036412 citedByCount "144" @default.
• W2022036412 countsByYear W20220364122012 @default.
• W2022036412 countsByYear W20220364122013 @default.
• W2022036412 countsByYear W20220364122014 @default.
• W2022036412 countsByYear W20220364122015 @default.
• W2022036412 countsByYear W20220364122016 @default.
• W2022036412 countsByYear W20220364122017 @default.
• W2022036412 countsByYear W20220364122018 @default.
• W2022036412 countsByYear W20220364122019 @default.
• W2022036412 countsByYear W20220364122020 @default.
• W2022036412 countsByYear W20220364122021 @default.
• W2022036412 countsByYear W20220364122022 @default.
• W2022036412 countsByYear W20220364122023 @default.
• W2022036412 crossrefType "journal-article" @default.
• W2022036412 hasAuthorship W2022036412A5017020283 @default.
• W2022036412 hasAuthorship W2022036412A5024903237 @default.
• W2022036412 hasAuthorship W2022036412A5026275950 @default.
• W2022036412 hasAuthorship W2022036412A5032064265 @default.
• W2022036412 hasAuthorship W2022036412A5040852969 @default.
• W2022036412 hasAuthorship W2022036412A5046648650 @default.
• W2022036412 hasAuthorship W2022036412A5056687099 @default.

• next